Pay in 4 interest-free payments of $6.35 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
No Accumulation with Repeated Dosing: A first-in-human study of recombinant human T4 (0.0525 g/kg IV) showed dose-proportional increases in Cmax and AUC, consistent terminal clearance across cohorts, and no obvious accumulation after 10 consecutive daily doses (PMID 34346165)
New Epilepsy therapies in development
Avoid creating foam or bubbles during this process
The molecule responsible was a tiny copper-binding tripeptide that drops 60% by age 60 and influences thousands of your genes
Compounding pharmacies make customized medicines for individual patients, and under section 503A of the Food, Drug, and Cosmetic Act, a pharmacy can compound from a bulk substance only if that substance has an official quality monograph, is a component of an FDA-approved drug, or has been formally added to an approved bulks list. BPC-157 qualifies on none of those counts, which is why the FDA placed it in Category 2 of its 503A bulk-substance review in September of 2023
Evidence for the presence of phospholipid hydroperoxide glutathione peroxidase in human platelets: implications for its involvement in the regulatory network of the 12-lipoxygenase pathway of arachidonic acid metabolism
